Plain-English translation of NCT07091357 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested , a new medication designed to treat seasonal allergic rhinitis in people whose symptoms were not well controlled by standard allergy medications. Researchers studied whether this medication was safe and effective by comparing it to a placebo (inactive injection) in about 108 participants. The trial examined how well the medication worked and how the body processed it.
Many people with seasonal allergic rhinitis do not get adequate relief from existing treatments like nasal steroid sprays or antihistamines. This trial was designed to determine whether this new injectable treatment could offer a better option for people whose allergies continue to cause significant symptoms despite standard care.
Participants received either one of two doses of the new injection or a placebo injection, and visited the clinic for assessments during their allergy season. They completed daily symptom diaries to track how their allergies responded to treatment. The study examined their symptoms, safety, and how their body responded to the medication over the course of the trial.
AI-generated summary from trial data ยท Oct 3, 2026 ยท Not medical advice
China
Phase
Testing effectiveness
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Enrollment target
~108 participants
Started
August 2025
Primary completion
December 2025
Age range
18 Years โ 75 Years
Last updated on clinicaltrials.gov in August 2026.